Learn More
A highly sensitive and specific assay for the quantitation of the anticancer agent dolastatin-10 (DOL-10) in human plasma is described. The method was based on the use of electrospray ionization-high-performance liquid chromatography/mass spectrometry (ESP-LC/MS). The analytical procedure involved extraction of plasma samples containing DOL-10 and the(More)
We describe a method to learn to make sequential stopping decisions, such as those made along a processing pipeline. We envision a scenario in which a series of decisions must be made as to whether to continue to process. Further processing costs time and resources, but may add value. Our goal is to create, based on historic data, a series of decision rules(More)
A high-performance capillary electrophoresis (HPCE) assay was used to determine the concentration of a potent cytotoxic agent, dolastatin-10, in human plasma. Following extraction from plasma, using a solid-phase C18 cartridge, capillary zone electrophoresis was used to separate, detect and quantitate dolastatin-10 using the structurally related compound(More)
The very potent antimitotic and anticancer agent, dolastatin-10 (DOL-10), currently undergoing testing in a phase II clinical trial, has been quantitated previously in human plasma by high-performance capillary electrophoresis (HPCE). This method provides a lower limit of detection of 25 ng/ml DOL-10 from extracted patient samples. Without changes in(More)
  • 1